Related references
Note: Only part of the references are listed.Systems Pharmacology to Predict Drug Toxicity: Integration Across Levels of Biological Organization
Jane P. F. Bai et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period
Rafael Barcena et al.
JOURNAL OF HEPATOLOGY (2013)
Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide
Biao Cheng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Hesperetin: An inhibitor of the transforming growth factor-β (TGF-β) signaling pathway
Yong Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
In Vitro and In Vivo Genotoxicity Assessment of Aristolochia manshuriensis Kom.
Youn-Hwan Hwang et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2012)
Investigative safety science as a competitive advantage for Pharma
Jonathan Moggs et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Charting, Navigating, and Populating Natural Product Chemical Space for Drug Discovery
Hugo Lachance et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice
Lan Ye et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2012)
Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI
Mohadeseh Dastpeyman et al.
MEDICAL ONCOLOGY (2012)
Post-market drug safety evidence sources: an analysis of FDA drug safety communications
Chieko Ishiguro et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Hesperetin, a potential therapy for carcinoid cancer
Barbara Zarebczan et al.
AMERICAN JOURNAL OF SURGERY (2011)
Cytoscape 2.8: new features for data integration and network visualization
Michael E. Smoot et al.
BIOINFORMATICS (2011)
Pharmacological Mechanism-Based Drug Safety Assessment and Prediction
D. R. Abernethy et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Quantitative knowledge-based analysis in compound safety assessment
Svetlana Bureeva et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 1. Method and Assessment of Virtual Screening
Xiaofeng Liu et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
GPU Accelerated Chemical Similarity Calculation for Compound Library Comparison
Chao Ma et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Using information mining of the medical literature to improve drug safety
Kanaka D. Shetty et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2011)
Silibinin: A novel inhibitor of Aβ aggregation
Fei Yin et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach
Shoude Zhang et al.
MEDCHEMCOMM (2011)
Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework
Yoshihiro Yamanishi et al.
BIOINFORMATICS (2010)
Technical challenges in designing post-marketing eCRFs to address clinical safety and pharmacovigilance needs
Zhengwu Lu
CONTEMPORARY CLINICAL TRIALS (2010)
The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
Robert A. Copeland
EXPERT OPINION ON DRUG DISCOVERY (2010)
Targeting silibinin in the antiproliferative pathway
Lei Li et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Silibinin Attenuates Cardiac Hypertrophy and Fibrosis Through Blocking EGFR-Dependent Signaling
Wen Ai et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Centrality measure in graphs
D. J. Klein
JOURNAL OF MATHEMATICAL CHEMISTRY (2010)
A side effect resource to capture phenotypic effects of drugs
Michael Kuhn et al.
MOLECULAR SYSTEMS BIOLOGY (2010)
The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology
Colin J. D. Ross et al.
THYROID (2010)
Growth Inhibition and Regression of Lung Tumors by Silibinin: Modulation of Angiogenesis by Macrophage-Associated Cytokines and Nuclear Factor-kappa B and Signal Transducers and Activators of Transcription 3
Alpna Tyagi et al.
CANCER PREVENTION RESEARCH (2009)
The future of drug safety testing: expanding the view and narrowing the focus
James L. Stevens et al.
DRUG DISCOVERY TODAY (2009)
Decision support methods for the detection of adverse events in post-marketing data
M. Hauben et al.
DRUG DISCOVERY TODAY (2009)
Predicting new molecular targets for known drugs
Michael J. Keiser et al.
NATURE (2009)
In silico toxicology for the pharmaceutical sciences
Luis G. Valerio
TOXICOLOGY AND APPLIED PHARMACOLOGY (2009)
Prediction of drug-target interaction networks from the integration of chemical and genomic spaces
Yoshihiro Yamanishi et al.
BIOINFORMATICS (2008)
Computational toxicology in drug development
Wolfgang Muster et al.
DRUG DISCOVERY TODAY (2008)
Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels
Richard D. Verschoyle et al.
EUROPEAN JOURNAL OF CANCER (2008)
Quantifying the relationships among drug classes
Jerome Hert et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2008)
Plant-derived natural product research aimed at new drug discovery
Hideji Itokawa et al.
JOURNAL OF NATURAL MEDICINES (2008)
Aristolochic acid nephropathy: A worldwide problem
Frederic D. Debelle et al.
KIDNEY INTERNATIONAL (2008)
Natural products to drugs: natural product-derived compounds in clinical trials
Mark S. Butler
NATURAL PRODUCT REPORTS (2008)
Network pharmacology: the next paradigm in drug discovery
Andrew L. Hopkins
NATURE CHEMICAL BIOLOGY (2008)
Drug target identification using side-effect similarity
Monica Campillos et al.
SCIENCE (2008)
DrugBank: a knowledgebase for drugs, drug actions and drug targets
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2008)
Modeling promiscuity based on in vitro safety pharmacology profiling data
Kamal Azzaoui et al.
CHEMMEDCHEM (2007)
Relating protein pharmacology by ligand chemistry
Michael J. Keiser et al.
NATURE BIOTECHNOLOGY (2007)
Exploration of biological network centralities with CentiBiN
Bjoern H. Junker et al.
BMC BIOINFORMATICS (2006)
Natural products to drugs: natural product derived compounds in clinical trials (vol 22, pg 162, 2005)
MS Butler
NATURAL PRODUCT REPORTS (2006)
Graph-based methods for analysing networks in cell biology
Tero Aittokallio et al.
BRIEFINGS IN BIOINFORMATICS (2006)
A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy
J Abraham et al.
SOCIAL SCIENCE & MEDICINE (2005)
Natural products to drugs: natural product derived compounds in clinical trials
MS Butler
NATURAL PRODUCT REPORTS (2005)
Network biology:: Understanding the cell's functional organization
AL Barabási et al.
NATURE REVIEWS GENETICS (2004)
The role of natural product chemistry in drug discovery
MS Butler
JOURNAL OF NATURAL PRODUCTS (2004)
Cytoscape: A software environment for integrated models of biomolecular interaction networks
P Shannon et al.
GENOME RESEARCH (2003)
Natural product hybrids as new leads for drug discovery
LF Tietze et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Concordance of the toxicity of pharmaceuticals in humans and in animals
H Olson et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2000)
Share Paper
